This post was originally published on Medscape
You will shortly be re-directed to the publisher's website
The Phase 3 PADMA trial showed that palbociclib plus endocrine therapy doubled progression-free survival compared with chemotherapy in high-risk HR+/HER2− metastatic breast cancer.
Medscape Medical News